Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether sutent (sunitinib)is effective in
preventing tumor recurrence in patients with high risk bladder cancer who have previously had
chemotherapy and cystectomy (bladder removal).
A 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal.
The patients are followed up to 2 years.